ArticleJACC. Advances2026
10-Year Excess Mortality After First-Time Non-ST-Segment Elevation Myocardial Infarction: The Western Denmark Heart Registry.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn ST-segment elevation myocardial infarction patients, recent evidence showed an almost similar 10-year mortality in 90-day survivors when compared with a matched general population. Whether this finding also applies to contemporary patients with non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear.
objectivesThe objective of the study was to examine excess mortality in first-time NSTEMI patients treated with percutaneous coronary intervention (PCI) compared with a matched general population during the landmark periods of 0 to 30 days, 31 to 90 days, and 91 days to 10 years.
methodsFirst-time NSTEMI patients treated with PCI were identified in the Western Denmark Heart Registry from 2010 to 2022. Mortality was compared with a general population cohort matched by age, sex, and calendar year.
resultsThe study included 10,748 first-time NSTEMI patients treated with PCI and 53,739 matched individuals. The median follow-up was 6.0 (Q1-Q3: 3.4-9.2) years. NSTEMI patients had higher mortality in all landmark periods than the general population: 1.9% (95% CI: 1.6-2.2) excess mortality from 0 to 30 days (HR: 8.90; 95% CI: 7.40-10.68), 0.5% (95% CI: 0.3-0.7) from 31 to 90 days (HR: 2.54; 95% CI: 2.06-3.15), and 6.1% (95% CI: 4.8-7.5) from 91 days to 10 years (HR: 1.26; 95% CI: 1.21-1.32). Notably, this excess risk was almost exclusively confined to patients with a high comorbidity burden (excess mortality 22.0%; 95% CI: 19.1-24.9).
conclusionsAmong first-time NSTEMI patients treated with PCI, 90-day survivors had a substantially higher 10-year excess mortality than the matched general population. This excess mortality was primarily driven by NSTEMI patients with a high baseline comorbidity burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.